

CodeBreak 200: A clinical trial for patients with non-small cell lung cancer (NSCLC) whose cancer has the *KRAS G12C* mutation



Why is the CodeBreak 200 clinical trial being done?

The CodeBreak 200 clinical trial is evaluating the effectiveness and safety of a study drug known as sotorasib (the proposed generic name for AMG 510) compared with docetaxel (an approved drug used to treat cancer) in previously treated patients with non-small cell lung cancer (NSCLC) containing the *KRAS G12C* mutation.

How do you know if your cancer has the *KRAS G12C* mutation?

You may have already been tested for genetic mutations related to cancer. You can ask your doctor about this testing, which is called biomarker testing, to find out about the *KRAS G12C* mutation. You or your doctor can also [contact an Amgen Medical Information Healthcare Professional \[hyperlink to Contact modal\]](#) for more information.

Are you eligible to participate?

Key eligibility criteria for the CodeBreak 200 clinical trial include:

- You have been diagnosed with NSCLC that has spread to areas near the lungs and can't be removed by surgery or that has spread to other parts of the body
- Your cancer contains the *KRAS G12C* mutation
- You are age 18 years or older
- You have received prior treatment with chemotherapy and an anti-cancer drug known as a checkpoint inhibitor

If you want more information about CodeBreak 200 and whether you are eligible to participate in this clinical trial, please visit **CodeBreakTrials.com** and talk to your doctor.